Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome.
Swanink, C M, Vercoulen, J H, Galama, J M et al. · The Journal of infectious diseases · 1996 · DOI
Quick Summary
This study compared immune system markers in blood samples from 76 ME/CFS patients and 69 healthy controls to see if immune abnormalities could explain fatigue severity. Researchers found one immune marker (CD11b on CD8 cells) was lower in ME/CFS patients, but most other immune measures were similar between groups, and none of these markers correlated with how severe a patient's fatigue or depression was.
Why It Matters
This study addressed a critical question in ME/CFS research: whether measurable immune abnormalities drive symptom severity. By directly testing whether immune markers could serve as diagnostic or prognostic tools, the research provides important negative evidence that helps redirect diagnostic efforts and clarifies which immunologic features are associated with the disease versus which are clinically meaningful.
Observed Findings
CD11b expression on CD8+ T cells was significantly decreased in CFS patients compared to controls
Previously reported increases in CD38 and HLA-DR on immune cells were not replicated
Endotoxin-stimulated production of TNF-α and IL-1β was significantly reduced in CFS patients
No significant differences in circulating cytokine levels between CFS and control groups
Immunologic test results did not correlate with fatigue severity, depression scores, or functional impairment measures
Inferred Conclusions
Immune abnormalities in CFS are inconsistent with previous reports and do not correlate with clinical symptom severity
These immunologic tests cannot serve as reliable diagnostic biomarkers for individual CFS patients
Simple measurement of standard immune markers is insufficient to explain the variable clinical presentation of CFS
Remaining Questions
Why do some previously reported immune abnormalities (CD38, HLA-DR) fail to replicate in this larger cohort?
What mechanisms could explain the reduced endotoxin-stimulated cytokine response if it is not directly linked to symptom severity?
What This Study Does Not Prove
This study does not establish that immune dysfunction plays no role in ME/CFS pathogenesis—only that the specific markers measured do not correlate with symptom severity or functional impairment in individual patients. Absence of correlation with fatigue scores does not mean the immune changes are irrelevant; they may still contribute to disease mechanisms in ways not captured by these particular clinical measures. Cross-sectional design prevents determination of causality.